Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24908097 | 0.92 | LRRK2 (0.40) | LRRK2NLRP3HSP90AA1HSP90AB1 | |
| SCHEMBL24908099 | 0.89 | CHRNB2 (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL21238766 | 0.79 | DRD2 (0.35) | LRRK2NLRP3HSP90AA1HSP90AB1CHRNB2 | |
| SCHEMBL20908039 | 0.78 | CYP11B1 (0.39) | NLRP3HSP90AA1HSP90AB1CYP11B1CYP11B2 | |
| SCHEMBL24923652 | 0.73 | HSP90AA1 (0.37) | LRRK2HSP90AA1HSP90AB1KDM5B | |
| SCHEMBL22518596 | 0.71 | LRRK2 (0.38) | LRRK2 | |
| SCHEMBL25018461 | 0.70 | LRRK2 (0.36) | LRRK2 | |
| SCHEMBL22474446 | 0.70 | LRRK2 (0.43) | LRRK2 | |
| SCHEMBL17998057 | 0.70 | OGA (0.39) | LRRK2HSP90AA1HSP90AB1 | |
| SCHEMBL26141130 | 0.70 | AADAT (0.35) | LRRK2HSP90AA1HSP90AB1KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885NLRP3 1658/4885HSP90AA1 1627/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885NLRP3 1658/4885HSP90AA1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.